Intuitive Surgical (NASDAQ: ISRG) has been a pioneer in robot-assisted surgery, first with its da Vinci surgical system, and more recently with its Ion endoluminal system, which is used to perform robotic-assisted bronchoscopy (a less invasive way to look at suspicious lung nodules).
The company makes its revenue from selling its systems to hospitals and surgical centers, servicing them, and providing a steady stream of the disposable items its robots use up during operations. It has a wide moat in its niche.
However, its shares are trading near a 52-week low, down more than 47% year to date. Should investors view that plunge as an opportunity or a signal for further caution? Let's take a look.
For further details see:
Down Nearly 50%, Is This Growth Stock Still a Buy?